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Abstract: We have designed and synthesized two novel cobalt coordination compounds using
bumetanide (bum) and indomethacin (ind) therapeutic agents. The anti-inflammatory effects of
cobalt metal complexes with ind and bum were assayed in lipopolysaccharide stimulated RAW
264.7 macrophages by inhibition of nitric oxide production. Firstly, we determined the cytotoxicity
and the anti-inflammatory potential of the cobalt compounds and ind and bum ligands in RAW
264.7 cells. Indomethacin-based metal complex was able to inhibit the NO production up to 35%
in a concentration-dependent manner without showing cytotoxicity, showing around 6–37 times
more effective than indomethacin. Cell cycle analysis showed that the inhibition of NO production
was accompanied by a reversion of the differentiation processes in LPS-stimulated RAW 264.7 cells,
due to a decreased of cell percentage in G0/G1 phase, with the corresponding increase in the number
of cells in S phase. These two materials have mononuclear structures and show slow relaxation
of magnetization. Moreover, both compounds show anti-diabetic activity with low in vitro cell
toxicities. The formation of metal complexes with bioactive ligands is a new and promising strategy
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to find new compounds with high and enhanced biochemical properties and promises to be a field of
great interest.
Keywords: bumetadine; indomethacin; cobalt; coordination compound; single-ion magnet;
inflammatory; diabetes
1. Introduction
The increasing consumption of sugar on our daily diet has posed diabetes as a world-wide
first-line problem of which society is becoming conscious. Diabetes mellitus is a disease that manifests
when the pancreas does not produce enough insulin (type I) or when the body cannot effectively use the
insulin it produces (type II). Some metal ions have shown insulin-like effects by supporting the signal
transduction of insulin and reducing the production of cytokines, triggering a cascade of events leading
to beta-cell death during the pancreatic inflammatory process in the course of disease. Thus, there is a
growing interest of the scientific community in the development of new drugs that improve diabetes
treatment efficacy showing minor adverse reactions and using different administration routes. Each
class of drugs has different mechanisms of action. Given that commonly used drugs are associated with
several adverse effects, it is of great interest to explore new drugs that can fight this disease effectively
with minimal side effects [1]. Recent studies aim to develop new drugs that can be administered orally
for the treatment of diabetes [2,3]. Coordination compounds have demonstrated to inhibit enzymes
that play a major role in modulating insulin sensitivity [4,5]. The design of these novel materials based
on metal ions could be an excellent tool to improve the distribution and, therefore, the effectiveness
of metals as oral anti-diabetic agents in the treatment of diabetes mellitus, giving an alternative to
traditional insulin therapy.
In recent years, we have synthesized novel multidimensional coordination compounds, with
fascinating structures and interesting physical and biological properties, by combining different
transition metal ions with different organic ligands, such as triazolopyrimidine derivative ligands [6,7]
and nitrogen ligands with carboxylate groups [8]. More specifically, in the field of diabetes, we have
designed Zn- and V-based compounds [9,10] with potential application in the treatment of this disease,
a pathology in which Zn compounds have shown promising hypoglycemic properties [11]. Other
materials based on different metal ions, such as vanadium compounds, have shown promising activity
as hypoglycemic agents for the pharmacotherapy of diabetes [12].
In a parallel manner, the use of inorganic medicinal chemistry has been substantially increased over
the past few decades, being focused on the development of metal complexes for the treatment of several
diseases, such as cancer, inflammatory, or autoimmune diseases [13]. More interestingly, there are
studies on the benefits of anti-diabetic agents with anti-inflammatory properties. In particular, recent
data suggest that immunomodulatory treatments may have beneficial effects on glycemia, b-cell function,
and insulin resistance [14]. Therefore, developing of a drug with insulinomimetic-anti-inflammatory
duality is undoubtedly a great advance to face up to diabetes disease.
During inflammation process, different molecular routes and a wide variety of protein kinases are
activated, as MAPK (mitogen-activated protein kinases), JAK (Janus-activated kinases), PI3K/AKT
(phosphatidylinositol-3-kinase). As a consequence, several transcription factors related to the
proliferation and inflammation routes are activated in response to these protein kinases, for example,
STAT (signal transducer activator of transcription), NF-kB (nuclear factor kappa B), activation proteins
1 (AP-1), or HIF-1 (hypoxia inducible factor 1-α), leading to the expression of pro-inflammatory
genes that encode pro-inflammatory enzymes as iNOS (nitric oxide synthase inducible) and COX-2
(cyclooxyenase-2), responsible for the synthesis of eicosanoids and other proteins mediators, as
cytokines and interleukins. Disturbing the activation of these transcription factors can produce
aberrant cell growth, carcinogenic cell transformation, angiogenesis, and metastasis.
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Nitric oxide (NO) is a very important mediator in acute or chronic inflammation. This nitrogen
radical is produced by constitutive and inducible nitric oxide synthases. The inducible enzyme
is activated in response to pro-inflammatory signals, such as LPS (bacterial lipopolysaccharide),
enterotoxin, or cytokines as TNFα (tumor necrosis factor α) or INF- γ (interferon-γ) in macrophages,
hepatocytes, and endothelial cells. The reduction of NO can be produced by direct scavenger action of
NO Radicals, iNOS inhibition enzyme activity, and/or iNOS gene expression inhibition. In this study,
the inhibition of NO production in activated LPS RAW macrophage cells have been used as an indirect
marker of the inflammatory process.
To construct novel materials, in this case, we have chosen bumetanide (bum) and indomethacin
(ind) anti-inflammatory agents (Scheme 1).
Indomethacin (1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3 acetic acid) is a nonsteroidal
anti-inflammatory drug (NSAID) with very effective antipyretic, analgesic, and anti-inflammatory
activity. Its pharmacological effects consist of an inhibition of cyclooxygenase enzyme (COX), reducing
the synthesis of prostaglandins. Especially, ind inhibits the catalytic activity of the COX enzymes
(isoforms COX-1 and COX-2), producing the inhibition of prostaglandins synthesis via the arachinodonic
acid pathway, causing a reduction of pain, fever, and inflammation [15] due to their ability to reduce
blood flow, modulating nitric oxide pathways and vasoconstriction [16]. Ind is more powerful than
other NSAIDs commonly used as anti-inflammatory compounds, such as ibuprofen or aspirin [17].
Bum is a potent loop diuretic effective in the treatment of the oedema associated with different
inflammatory process, as congestive heart failure, hepatic and renal diseases, acute pulmonary
congestion, premenstrual syndrome, and diuresis during and after surgery. In relation to the
inflammatory process, bum has been associated with the Na+-K+-2Cl− co-transporter BSC2 (NKCC1),
which is regulated by inflammatory cytokine stimuli. This co-transporter is responsible for maintenance
of a selective permeability barrier in mammalian cells [18]. Bum is well known for its ability to inhibit
NKCC1 chloride-importer inhibitor [19]. However, bum inhibits the trans-membrane conductance
regulator CFTR GCI [20]. NKCC1 and CTFR are both involved in a variety of biological processes
ranging from the regulation of macrophage activation to the modulation of cytokine production.
Accordingly, we decided to work with these organic molecules as ligands, ind and bum, to form
coordination complexes due to the fact very few examples are reported so far. In this way, we could
offer to the scientific community multifunctional materials with different biomedical applications.
In particular, a perusal of the CCDC database shows that only the sodium and potassium salts of
bum ligand have been characterized [21]. On the other hand, only some examples of coordination
compounds based on copper [22], tin [23], and zinc [24] have been found for the ind molecule. All the
above-mentioned leads us to the conclusion that the biological application of coordination compounds
based on these therapeutic agents is almost unexplored.
Scheme 1. Bumetanide (left) and indomethacin (right) organic ligands used as drugs to construct
coordination compounds based on cobalt.
In order to obtain single-molecule magnets (SMMs) with biological properties, we chose cobalt due
to this metal ion generally exhibiting large magnetic moments and high anisotropy. On the one hand,
the fact that cobalt has such a predictable octahedral coordination sphere could help us control the
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structure of the mononuclear compound. In this sense, ind and bum are adequate because, possessing
a single carboxylate group, they may coordinate occupying two coordination positions in the cobalt
sphere. Being monoanionic ligands, coordination of two ligands by a cobalt center would balance the
charge to yield neutral cobalt-based monomeric complexes. Moreover, thanks to the large size of the
therapeutic agents, cobalt ions could be separated away in the crystalline structure to obtain novel
materials exhibiting interesting magnetic properties provided that they maintain a large anisotropy,
using either transition metal ions with first-order orbital angular momentum [25], such as CoII and
FeII, or very anisotropic lanthanide ions, such as DyIII [26]. Though these interesting magnets are
being mainly suggested for their applications in molecular spintronics and ultrahigh density magnetic
recording [27], their utility could also be extended to research in the field of biomedicine.
For all the above reasons, the milestone that we propose here was to synthesize novel cobalt
mononuclear coordination compounds with potential biomedical activities that, at the same time,
exhibit slow relaxation of magnetization. In this paper, we present two novel mononuclear coordination
compounds, [Co(bum)2(H2O)2](H2O)2 (1) and [Co(ind)2(EtOH)2] (3) (Hbum = bumetanide (2) and
Hind = indomethacin (4)), synthesized using conventional routes.
2. Results and Discussion
2.1. Description of the Structures
2.1.1. Structural Description of [Co(bum)2(H2O)2](H2O)2 (1)
Compound 1 crystallizes in the monoclinic P2/c space group. A perspective view on the molecular
structure of 1 is shown in Figure 1. Selected bond lengths are given in Table S1. The structure consists
of one mononuclear [Co(bum)2(H2O)2] neutral complex and two crystallization water molecules. Each
Co(II) ion shows a distorted octahedral CoO6 stereochemistry formed by two oxygen atoms in cis
positions belonging to two different water molecules and four oxygen atoms of carboxylate groups
pertaining to bumetanide ligands. Continuous shape measures confirm the large distortion of the
environment compared to an ideal octahedron (SOC = 5.89, see Table S3). The two Co–Obum bond
distances have values of 2.096(3) and 2.233(3) Å, whereas Co–Ow distance is 2.025(3) Å. The cis and trans
angles vary in the 60.51(13)–113.86(14)◦ and 147.7(2)–148.33(13)◦ ranges, respectively. It should be noted
that the most important parameter bringing the distortion of octahedral coordination environment is
due to the acute O1-Co-O2 bite angle of the carboxylate group (60.51(13)◦). This compound shows a
complex and beautiful hydrogen bonding network, in which O1W, O2W, O1-O5 and N2 atoms are
involved. These hydrogen bonds generate a 2D network with distances in the 2.630(5)–3.011(6) Å
range, among which that established in O1w-H1WA···O2 (2.630(5) Å) must be highlighted because it is
responsible for the relative coplanar disposition of the two coordinated bumetanide ligands. This 2D
hydrogen network can be described by anti-parallel chains constructed of these mononuclear entities
(Figure S3). Selected bond distances and hydrogen bonds are given in Table S1 and S2, respectively.
Figure 1. A perspective view on the molecular structure of [Co(bum)2(H2O)2].(H2O)2 (1). Crystallization
water molecule and hydrogen atoms have been omitted for clarity.
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To the best of our knowledge, it is the first time that a coordination compound with bumetanide
ligand has been synthesized.
2.1.2. Structural Description of [Co(ind)2(EtOH)2] (3)
Compound 3 crystallizes in the monoclinic C2/c space group. A perspective view on the molecular
structure of 3 is shown in Figure 2. Selected bond lengths are given in Table S2. The structure
of [Co(ind)2(EtOH)2] (3) consists of mononuclear compounds of cobalt with two ligands and two
coordinated solvent molecules (Figure 2). The asymmetric unit contains one cobalt atom, one ind
ligand, and one ethanol molecule. In the structure, each CoII atom is located on an inversion center and
exhibits a distorted octahedral CoO6 geometry established from four oxygen atoms of two carboxylate
groups pertaining to indomethacin ligands and two oxygen atoms from two different ethanol molecules.
CoII–Oind bond distances have values of 2.110(2) and 2.185(2) Å, whereas CoII–Oethanol distance is
2.025(3) Å. The cis and trans angles vary in the 61.15(8)–104.51(9)◦ and 152.04(12)–154.90(8)◦ ranges,
respectively. As a result, the distortion of the coordination environment with regard to an ideal
octahedron is lower than for 1 but still significant (SOC = 4.48, see Table S3).
Figure 2. A perspective view on the molecular structure of [Co(ind)2(EtOH)2] (3). Hydrogen atoms
have been omitted for clarity.
This compound shows a crystalline network that can be described by chains constructed of these
mononuclear entities highlighting the O1E-H1E···O2 hydrogen bond with a value of 2.606(3) Å. Selected
bond distances are given in Table S3.
2.2. Magnetic Properties
Alternating-current (ac) susceptibility measurements under an AC field of 3.5 Oe were performed
in order to study the spin dynamics of these cobalt-based compounds in view of the isolated nature
of the spin carriers in their crystal structures (closest Co···Co separations are of ca. 5.39 and 5.27 Å
mediated by intermolecular hydrogen bonds). As it is well-known, small distortions introduced in
the coordination environments of high-spin octahedral Co(II) centers break the degeneracy of the
4T1g ground state [28], causing substantial zero-field splitting (zfs) that plays a very important role
in the SIM behavior [29]. On accounts of previously reported magnetization measurements and ab
initio calculations, large values of zfs parameters are expected irrespective of their sign (leading to
easy-axis or easy-plane anisotropy) for distorted octahedral environments such as those present on
these compounds (as shown by CShMs: SOC = 5.89 and 4.48 for 1 and 3, respectively) [30]. However,
no frequency dependent signals were observed above 2 K in the absence of an applied external DC
field, which is probably related to the presence of fast quantum tunneling of the magnetization (QTM)
derived from intramolecular and/or strong hyperfine interactions with the I = 7/2 nuclear spin of the
Co(II) atom [31,32]. Instead, QTM is effectively suppressed by applying a DC field of 1000 Oe, in
such a way that both compounds exhibit SIM behavior with characteristic temperature-dependent
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in-phase (χM’) and out-of-phase (χM”) signals [33,34]. In particular, 1 presents the maxima in the χM”
signal for frequencies larger than 500 Hz (Figure 3), which allow performing further analysis (Figure 4).
However, maxima of compound 3 occur at too low a temperature as to be observed (see Figure 5).
Figure 3. Temperature dependence of the (a) χM’ and (b) χM” signals for compound 1 together with
the Arrhenius plot of the relaxation times.
Figure 4. Cole-Cole plots in the form of χM” vs χM’ for compound 1 under an applied field of 1 KOe.
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Figure 5. (a) χM’ vs T and (b) χM” vs T plots signals for compound 3.
Accordingly, Cole-Cole plots represented in the temperature region delimiting these maxima
(2–5 K range) show a well-defined semi-circular distribution that could be successfully fitted by means
of the Debye model (Figure 4) [35]. The resulting values of α range between 0.21 and 0.04, a wide
dispersion that suggests the presence of more than one mechanism involved in the spin relaxation of
1. The distribution of the relaxation times in the Arrhenius plot (expressed as ln(τ) vs 1/T, whereτis
extracted from the fit of χM” at each temperature) confirm the previous statement by showing a
curvilinear shape.
In any case, taking into account high-temperature range that follows the Arrhenius law, an energy
barrier for the reversal of the magnetization (Ueff) of 42.3 K and τ0 of 4.53 × 10–9 s are estimated through
the thermally activated Orbach process (Equation (1), see inset of Figure 3).The value of Ueff and τ0 fall
within the typical range found for SIMs based on octahedral Co(II) complexes [36,37].
τ = τ0 exp(Ueff/κBT) (1)
This kind of Arrhenius representation clearly deviating from linearity is commonly related to
the presence of additional relaxation mechanisms (such as filed-induced phonon bottleneck direct
relaxation, Raman relaxation and/or QTM), in good agreement with aforementioned α values [38].
Among these possible mechanisms, QTM was initially discarded given the absence of rapid increase in
the χM” curves at low temperature (below the maxima). In the direct and Raman processes, relaxation
follows τ–1 = CTn equation, where n should equal 1 and 9 for Kramers ions, respectively, for direct
and Raman processes, although values in the 1–6 range are acceptable in practice provided that
the relaxation takes place through phonons. Attempts to fit the relaxation times, though reliably
reproducing the experimental curve, gave rise to a diversity of results, most of which lack physical
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sense. Therefore, only Orbach and Raman were considered for the fitting process, making use of the
expressions gathered in Equation (2):
τ−1 = BRamanTn + τ0−1 exp(−Ueff/κBT) (2)
Results of the best fit are BRaman = 115(4) s–1, n = 2.9(3), τ0= 1.69 × 10–11 s and Ueff = 71(4) K, which
can be considered as relatively high compared to those previously reported for CoII based SIMs [39,40].
2.3. Anti-Diabetic Properties
The nematode Caenorhabditis elegans has proven to be an important animal model to study
the molecular mechanisms of drug effects and disease pathogenesis and for that, it has been used
extensively as a model organism since 1974. Many key findings with relevance for mammals were
discovered in this well-characterized model organism, it became first organism which was completely
sequenced, showed a strong conservation of biological principles between C. elegans and mammals
with approx. 60–80% of gene homologues between human and C. elegans [41]. This model has been
used extensively to study various diseases, including diabetes, an endocrine dysfunction resulting
from insulin deficiency or incapability of peripheral tissues to respond to insulin [42].
Results from the present study show that exposure of nematodes to increasing concentrations of
compound 1 resulted in a lack of acute toxicity, expressed by the lethality test, up to a dosage of 200
µM (Figure 6A). For compound 3, a statistically significant lethality level was only showed for 200 µM,
the highest tested dosage (Figure 6B).
Figure 6. Study of the anti-diabetic properties of compounds 1 and 3 in the nematode C. elegans.
(A) Lethality analysis for compound 1. (B) Lethality analysis for compound 3. (C) Changes in glucose
content in the nematodes after exposure of 100 µM of compounds 1 and 3, respectively. Results
represent the mean ± SEM of three independent experiments. * Statistically significant differences with
respect to 0 µM dosage (B) or to the control group (C).
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According to these results, the authors decided to test anti-diabetic potential of assayed compounds
(compound 1 and 3) by using the highest and non-toxic dosages for any of the two compounds, i.e.,
100 µM dosage. Figure 6C presents glucose levels in the nematodes after four days exposure to 100 µM
of compounds 1, 3 or to control vehicle, bum (compound 2) and ind (compound 4). Results showed that
compound 1 presented statistically significant lower glucose levels that control group (mean reduction
of 31%, p < 0.05). In the same way, compound 3 exhibited lower glucose than nematodes from the
control group (24% less glucose, p < 0.05). According to these results, we can conclude that both,
compounds 1 and 3 might be endowed with anti-diabetic properties, since one of the main features of
diabetes is an excess of glucose in the organism, irrespective of the cause of this excess (diminished
insulin production or enhanced diabetes resistance). Cobalt usefulness in the management of diabetes
and glycemic control in streptozotocin-diabetic rats has been previously reported [43], displaying those
cobalt-treated diabetic rats demonstrated an enhanced ability to clear a glucose overload compared to
the untreated control group. However, as far as we know, this is the first study based on cobalt-based
compounds on glucose control in C. elegans. Thus, the present research demonstrates, on one hand,
that the newly synthetized compounds might be of interest in the management of diabetes. On the
other hand, it is corroborated here that the potential of the use of a high-throughput screening model
like C. elegans to test cobalt-based newly designed compounds for the putative treatment of altered
glucose metabolism-dependent diseases.
2.4. Raw 264.7 Cell Viability
Traditionally, small organic molecules have been described with anti-cancer and anti-inflammatory
properties useful as drugs [44,45]. Currently, has been reported that metal complexes possess remarkable
advantages that render them as attractive alternatives to small organic molecules for the development
of potential therapeutic agents, among others they show higher half-lives to allow their preferential
tissue accumulation, due to their highest vascular permeability that permits their retention on tumor
tissues [46].
The coordination of bioactive molecules to metal ions is a common strategy to improve the
therapeutic potency and/or to reduce the toxicity of drugs molecules, giving their new properties as
increased lipophilicity profiles compared to the free ligands, allowing to pass through cell membranes
more easily. Additionally, the complexation of nonsteroidal anti-inflammatory drugs (NSAIDs) may
be an effective strategy to reduce the adverse side effects of these agents [47].
Cytotoxicity of compounds 1, 2, 3, and 4 were determined on RAW 264.7 murine macrophage cells
to establish infra-cytotoxic work concentrations and to assure that antiflammatory effects were due to
an inflammatory process and not due to their cytotoxicity. The cytotoxicity range was determined by
the well-established MTT assay, where (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
is transformed to formazan into peroxisomes from viable cells, while dead cells lose the ability and
therefore show no signal. IC50, the total concentration of inhibitor required to reach 50% inhibition, were
calculated by nonlinear regression taking the concentration required to bring the curve down to point
half way between the top and bottom plateaus of the curve (using the SigmaPlot program). The results
showed similar cytotoxicity values for all compounds under study in the conditions assayed (from 0
to 100 µg/mL) (Figure 7). Concretely, IC50 concentrations (50% inhibition) were 72.10 ± 6.63 µg/mL
for compound 1, 71.74 ± 9.64 µg/mL for compound 2, 65.27 ± 1.41 µg/mL for compound 3, and
72.55 ± 4.12 µg/mL for compound 4 (Figure 7). Moreover, we determine the compound concentrations
required for 20% and 80% of growth inhibition (IC20 and IC80) to analyze the entire cytotoxicity range
(Table 1).
Based on these results, sub-cytotoxic concentrations were used in the next assays; specifically, the
concentrations values used in the determination of anti-inflammatory response were IC50, 3/4 IC50,
1/2 IC50, and 1/4 IC50.
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Figure 7. Effect of compounds 1, 2, 3, and 4, on cell proliferation in RAW 264.7 macrophage murine
cells, after 72 h of treatment with assayed compounds in a wide range of concentration from 0 to
100 µg/mL. Each point represents the mean value ± S.D. of at least two independent experiments
performed in triplicate. IC20, IC50, and IC80 are the concentrations required for growth inhibition of
20%, 50% and 80%.
Table 1. Growth-inhibitory effects of compounds 1, 2, 3, and 4 on RAW 264.7 monocyte/macrophage
murine cells.
Compound IC20 IC50 IC80
1 54.04 ± 6.31 72.10 ± 6.63 103.63 ± 10.4
2 55.83 ± 6.98 71.74 ± 9.64 97.16 ± 0.43
3 54.54 ± 3.61 65.27 ± 1.41 78.49 ± 3.82
4 58.37 ± 6.09 72.55 ± 4.12 93.48 ± 3.04
2.5. Nitric Oxide Production
Having in mind that the ligand and complex are anti-inflammatory compounds, both must
show anti-inflammatory properties. Nevertheless, it has been reported that the formation of the
anti-inflammatory complex may have some additional advantages over the ligand. Thus, for example,
the Zn-aceclofenac complex, reduces the formation of stomach ulcers in comparison to aceclofenac,
probably by masking the free carboxylic group of the aceclofenac in the coordination complex. Both
Zn-complex and aceclofenac showed abilities to reduce inflammatory edema in the paws of rats
challenged by carrageenan, but the Zn-aceclofenac complex induced fewer ulcers in comparison with
aceclofenac alone [48].
Several research groups have development different studies to develop new anti-inflammatory
complex compounds, thus have been reported Co(II) complexes of deprotonated mefenamic
acid, showed scavenger properties from DPPH (2,2-diphenylpicrylhydrazyl). Furthermore, Co(II)
complexes of naproxen [49], tolfenamic acid [50], and Mn (II) complexes of tolfenamic, have shown
anti-inflammatory properties [51].
In the inflammatory response process, nitric oxide, NO, is released as an intermediate or second
messenger. The enzymatic production of NO is cell type specific, with cytokine-driven inducible NOS
(iNOS) noted initially for the burst of higher levels as part of the inflammatory activation process.
RAW 264.7 murine macrophage cells produce the highest release of NO during the inflammatory
response, being an especially indicated model in anti-inflammatory compounds screening studies.
As the nitrites concentration is proportional to the NO release, in this study the anti-inflammatory
potential of the compounds assayed was analysed by measuring of nitrites in cell culture medium.
Firstly, macrophages 264.7 were activated with LPS for 24 h. After this stimulation period cells were
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incubated with compound 1, 2, 3, and 4, for 24 h. The Griess reaction was used to determine the nitrite
concentration in all the samples as described in Section 3.
Our results showed that all compounds tested produce an inhibition of NO release, being
higher in compound 3 versus their vehicle (Figure 8). In depth, after 24 h of incubation, the higher
anti-inflammatory effect was produced by the compound 3, indomethacin-Co complex, with a 40.92% of
NO inhibition with respect to the positive control (only LPS treated control cells). This percentage was
six times higher than the inhibition achieved only by the indomethacin ligand treatment (compound 4,
6.78% of NO inhibition).
Figure 8. Effect of compounds 1, 2, 3, and 4 on the release of nitrites assay in RAW 264.7 macrophage
murine cells. After activation of the inflammatory process by incubation with LPS for 24 h, the
compounds were incubated for 24 h at concentrations de 3/4 × IC50, 1/2 × IC50, 1/4 × IC50. The data
represent the mean ± S.D. of at least two independent experiments performed in triplicate.
In contrast, bumetanide and bumetanide-cobalt complex showed similar depressed NO levels at
54 µg/mL (3/4 × IC50 concentration) and non-significant differences were found. At longer incubation
times (48 and 72 h), all compounds produced the inhibition of the inflammatory processes, although
not significant differences were found between cobalt compounds, compounds 1 and 3, and its ligand,
compounds 2 and 4 (data not show).
Therefore, the anti-inflammatory effect study was deeply performed for compound 3, and we
calculated the effective doses at 50% of NO inhibition (EC50NO) after 24 h of treatment of compounds
3 (indomethacin-Co complex), and 4 (indomethacin ligand) (Figure 9). Our data showed that the
EC50NO of compound 3 was less than the one found for compound 4. Concretely, the EC50NO for
compound 3 was 28.76 ± 4.23 µg/mL, and the EC50NO for the compound 4 was 35.92 ± 0.97 µg/mL.
Figure 9. Sigmoidal curves of the effect of the compounds 3 (blue) and 4 (ind, orange) on the
release of nitrites in RAW 264.7 macrophage murine cells. Clearly, the curves corresponding
to metal-complex compound (3, EC50NO = 28.76 ± 4.23 µg/mL) are below to the ligand one (4,
EC50NO = 35.92 ± 0.97 µg/mL). The data represent the mean ± S.D. of at least two independent
experiments performed in triplicate.
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2.6. Cell Cycle Arrest and Distribution
Flow cytometry is generally used to measure DNA ploidy, as well as alterations in cell-cycle
profiles. Differentiation processes increase the cell population in G0/G1 phase where these cells
expressed its physiological characteristics. The information obtained by this technique includes the
visualization of cell subpopulations with different DNA contents. For each nucleus subpopulation
identified, the parameters of population size, fractions of nuclei in each phase of the cell cycle and
computation of DNA ratios can be discerned.
Concretely, the distribution of cells in each of cell cycle phases was analysed by flow cytometry with
propidium iodide (IP) stained (Figure 10). DNA histogram analysis revealed that the four compounds
were able to revert the cell cycle arrest induced by LPS. The arrest of cell cycle in LPS-induced RAW
264.7 cells produced a 100% of detention in G0/G1 phase (positive control). After 24 h of treatment
with the products 1, 2, 3, and 4, we observed a decrease of the number of cells in the G0/G1 phase,
with the consequent increase of the number of cells in the S phase. Changes in G2/M phase were
not significant. This recovery of cell cycle with respect to control cells (only LPS treated) could be
a consequence of the anti-inflammatory effects produced by the compounds tested, which lead an
increase in cell division. These results showed not significant differences between the products assayed
at the concentrations used, indicating that all products assayed present anti-inflammatory effects at the
concentrations assayed.
Figure 10. Percentage of RAW 264.7 macrophage murine cells in the different phases of cellular cycle,
G0/G1, S and G2/M. Cells were treated with LPS for 24 h, to induced inflammatory process, after that
cells were treated with compound 1, 2, 3, and 4 for 24 h at its 1/2 × IC50 and 3/4 × IC50 concentrations.
In addition, results obtained for negative control (untreated cells) and positive control (cells only
treated with LPS) are showed. Data represent the mean ± S.D. of at least two independent experiments
performed in triplicate.
2.7. Stoichiometric Mixtures
To determine if the synthetized coordination compounds 1 and 3, were more effective than the
stoichiometric mixture of metal and ligands in the same proportions, we analyzed the liberation of nitric
oxide (NO) in response to the following mixture: M1 (bumetanide and Cobalt), M2 (indomethacin
and cobalt). For these experiments we used cobalt(II) nitrate hexahydrate in a 1:1 stoichiometry with
the corresponding ligands. After inflammation induction in murine macrophage/monocyte RAW
264.7 cells with LPS, as we described in Section 3, concentrations of free nitrites in cell medium were
determined after 24 h of treatment with increased concentrations of the mixtures (in the same range
used for the test of the complex compounds assayed) 17.5, 35.0, and 52.5 µg/mL.
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Results obtained showed that the stoichiometric mixtures had not any effect on NO production
inhibition as response to inflammatory process induced by LPS (Figure 11).
Figure 11. Effect of Co and stoichiometric Co-mixtures with bum and ind on the release of nitrites in
LPS RAW 264.7 activated macrophage murine cells. The stoichiometric mixtures were incubated for
24 h at concentrations of 17.5, 35.0, 52.5 µg/mL. The data represent the mean ± S.D. of at least two
independent experiments performed in triplicate. Key: p < 0.1 (*), p ≤ 0.01 (**), respect to LPS treated
positive control cells.
The percentage of NO production in respond to stoichiometric mixtures or cobalt are given
in Table 2. Curiously, stoichiometric mixture of cobalt and bumetanide seems to increase the NO
production (around a 45% greater than positive control) at the highest concentration, which could
be due to a possible pro-inflammatory effect. This surprising response is even more acute in the
cobalt treatments reaching values near to 72% higher than positive control at 17.5 and 35.0 µg/mL
concentrations, and up to 117% higher than positive control at 52.5 µg/mL concentration. These results
showed that the treatment with Co alone resulted be pro-inflammatory. This asseveration has been
supported by bibliography; in this way, the pro-inflammatory effect of the cobalt had been observed
since the mid-20th century [52,53].
Table 2. Percentage of release of nitrites in LPS RAW 264.7 activated cells in respond to stoichiometric
mixtures and Co.
Mixture 17.5 µg/mL 35.0 µg/mL 52.5 µg/mL
Co+Bu 116.39 ± 13.01 114.75 ± 3.28 145.90 ± 13.01
Co+Ind 104.10 ± 6.19 91.80 ± 10.62 104.10 ± 8.40
Co 175.41 ± 6.35 175.41 ± 8.52 217.21 ± 10.91
Furthermore, Co+2 and cobalt nanoparticles (CoNPs) have showed to induce inflammatory
process with increase of reactive oxygen species (ROS) and inflammatory cytokines in Balb/3T3 cells,
as TNFα, IL-1β, and IL-6 [54]. The recruit of inflammatory cells have been described in respond
to cobalt ions, mediated by TLR4 receptor, increasing the secretions of inflammatory chemokines
(IL-8 and CCL2) [55]. These pro-inflammatory effects has been also described in metal-on-metal
hip replacements, manufactured from a cobalt-chrome alloy [56]. With respect to our results in the
mixtures of the Co and bumetanide or indomethacin, probably these anti-inflammatory compounds
counteracted the pro-inflammatory effect of the cobalt, whereas in the treatment with the complexes,
the Co ions are completely kidnap by then, avoiding its inflammatory effect.
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2.8. Stability of Compounds in Solution
Crystals of complexes 1 and 3 were dissolved deuterated dimethylsulfoxide and proved to be
stable over several days without any sign of decomposition. The DMSO-d6 1H NMR spectra at 23 ◦C
for both complexes exhibit a number of resonances consistent with paramagnetic species having
resonances shifted over a 100 ppm range. In general, the in-plane hydrogens on the chelate exhibit
relatively large deviations from their diamagnetic reference values. In 1 for instance, signals located at
88.8 (W1/2 = 382 Hz) and 64.7 ppm (W1/2 = 208 Hz) were observed (Figure S1), whereas in 3, signals at
88.4 (W1/2 = 930 Hz) and 64.8 ppm (W1/2 = 446 Hz) could be detected (Figure S3). The observation
of these signals is uniquivocal proof that the complexes remain in solution. Interestingly, the 1H
NMR spectrum of complex 3 showed signals associated with diamagnetic ethanol (dH 1.06, 3.46 and
4.32 ppm), which is probably due to their exchange with DMSO solvent.
3. Materials and Methods
3.1. Materials and Physical Measurements
All reagents were obtained from commercial Sigma-Aldrich source (Spain) and used as received.
Elemental (C, H, and N) analyses were performed on a Leco CHNS-932 microanalyzer (Elemental
microanalysis Ltd., Okehampton, UK). IR spectra of powdered samples were recorded in the
400–4000 cm−1 region on a Nicolet 6700 FTIR spectrophotometer using KBr pellets.
3.2. Synthesis of [Co(bum)2(H2O)2](H2O)2 (1)
A solution containing cobalt(II) acetate tetrahydrate (0.0123) was mixed with other of bumetanide
(2, 0.0364 g) using the minimum volume of absolute ethanol as solvent, stirring and heating at
70 ◦C for 20 min. After evaporation at room temperature for 24 h, purple crystals suitable for
XRD characterization were obtained by vacuum filtration. Yield: 43%, based on Co. Anal. calcd
C34H46N4O14S2Co: C 47.61, H 5.40, N 6.53. Found: C 47.32, H 5.11, N 7.03.
3.3. Synthesis of [Co(ind)2(EtOH)2] (3)
A solution containing cobalt(II) acetate tetrahydrate (0.0123) was mixed with other of indomethacin
(4, 0.0359 g) using the minimum volume of ethanol absolute as solvent, stirring and heating at 70 ◦C
during 20 min. After evaporation at room temperature for 48 h, pink crystals suitable for XRD
characterization were obtained by vacuum filtration. Yield: 35%, based on Co. Anal. calcd
C42H42N2O10Cl2Co: C 58.34, H 4.90, N 3.24. Found: C 58.24, H 4.58, N 3.42.
3.4. Crystallographic Refinement and Structure Solution
Prismatic crystals for 1 and 3 were mounted on a glass fiber and used for data collection on a
Bruker D8 Venture with a photon detector equipped with graphite monochromated MoKα radiation
(λ = 0.71073 Å). The data reduction was performed with the APEX2 [57] software and corrected for
absorption using SADABS [58]. Crystal structures were solved by direct methods using the SIR97
program [59] and refined by full-matrix least-squares on F2 including all reflections using anisotropic
displacement parameters [60]. The OLEX2 software was used as a graphical interface [61]. Generally,
anisotropic temperature factors were assigned to all atoms except for hydrogen atoms, which are
riding their parent atoms with an isotropic temperature factor arbitrarily chosen as 1.2 times that of
the respective parent. In 1, only one H-atom of the water molecule was visible from Fourier maps
meanwhile the other hydrogen atom was modelled as a positional disorder in two alternative positions
(0.56:0.44 ratio). Final R(F), wR(F2) and goodness of fit agreement factors, details on the data collection
and analysis can be found in Table 3. CCDC numbers are 1836761 and 1836762 for 1 and 3, respectively.
These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via [62].
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Table 3. Crystallographic data and structure refinement details of all compounds.
Compound 1 3
Chem. form. C34H46N4O14S2Co C42H42Cl2N2O10Co
Form. weight 857.80 864.60
Cryst. system Monoclinic Monoclinic
Space group P2/c C2/c
a (Å) 20.470(3) 30.137(4)
b (Å) 5.267(2) 5.388(2)
c (Å) 18.294(3) 23.908(3)
α (◦) 90 90
β (◦) 96.252(3) 91.339(4)
γ (◦) 90 90
V (Å3) 1960.8(9) 3881.0(17)
Z 2 4
GOF a 1.077 1.034
Rint 0.1130 0.1023
R1 b / wR2 c [I > 2σ(I)] 0.0616 / 0.1269 0.0390 / 0.0662
R1 b / wR2 c (all data) 0.0971 / 0.1420 0.0662 / 0.0740
[a] S = [
∑
w(F02 – Fc2)2 / (Nobs – Nparam)]1/2 [b] R1 =
∑
||F0|–|Fc|| /
∑
|F0| [c] wR2 = [
∑
w(F02 – Fc2)2 /
∑
wF02]1/2;
w = 1/[σ2(F02) + (aP)2 + bP] where p = (max(F02,0) + 2Fc2)/3
3.5. Experiments in the Nematode Caenorhabditis Elegans
C. elegans strain Bristol N2 (wild-type), as well as the Escherichia coli OP50 strain were obtained
from the Caenorhabditis Genetics Center, University of Minnesota (Minneapolis–St. Paul, MN, USA).
Worms were maintained at 20 ◦C on nematode growth medium (NGM) agar plates carrying a lawn
of E. coli OP50. Synchronization of worm cultures was achieved by hypochlorite treatment of gravid
hermaphrodites. Two different analyses were performed on nematodes. First, a lethality assay [63]
was performed to determine the death rate derived from acute toxicity in a concentration-response
curve basis. A total of 10 ± 1 young adults were transferred into 24-well microplates, which contained
concentrations of compound 1 or compound 3 (ranging from 0 to 200 µM) and a negative control.
The exposure was carried out at 20 ◦C during 24 h in the absence of food. Then, the number of live
and dead worms was counted through visual inspection using a dissecting microscope. Death was
assumed when there was no movement during an observation period of 30 s. The second assay
consisted on the measurement of glucose content in the worms after four days of exposure to the
experimental compounds or to a negative control. After experimental exposure, 20 worms were
picked into a vial containing 200µL of ice-PBS buffer and centrifuged at 600× g to remove rest of
food and compounds. After removing the supernatant, worms were added with 100 µL of ice-PBS
and homogenized by a glass homogenizer. The resulting homogenate was used to measure glucose
content by a Spinreact kit (Spinreact: Girona, Spain). Glucose content was normalized by protein
content, which was measured using Pierce® BCA Protein Assay (Thermo Scientific: Rockford, IL,
USA). Glucose and protein content were measured in 96-well microplates in a Synergy Neo2 multiplate
reader (Biotek Instruments, Winooski, VT, USA). Lethality and glucose content experiments were
performed in triplicate. Statistical differences between compounds exposure with respect to the control
were tested by Student’s t test. In all analyses, significant differences were established at p < 0.05.
Statistical analysis was performed with SPSS 24.0 for Windows (IBM: Chicago, IL, USA).
3.6. Drugs
Compounds 1, 2, 3, and 4 were dissolved in DMSO at 5 mg/mL and stored at 4 ◦C. Before the
treatment the stock solutions were diluted in cell-culture medium to the adequate concentrations
for each experiment. In the C. elegans experiments drugs were used at a range concentration from
0 to 200 µM as indicated. For nitrite concentration, 3/4 × IC50, 1/2 × IC50, 1/4 × IC50 concentrations
were used (IC50, concentration causing 50% reduction growth). For cell cycle analysis, 3/4 × IC50 and
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1/2 × IC50 were used. All experiments were measured and compared to control untreated cells after 24,
48, or 72 h of treatment.
3.7. Cell Culture
A monocyte-lineage cell line was used, the murine macrophage-like RAW 264.7 cell line (ECACC no;
ATCC no) was cultured in DMEM medium supplemented with 2 mM glutamine, 10% heat-inactivated
FCS, 10,000 units/mL of penicillin, and 10 mg/mL of streptomycin, being incubated at 37 ◦C in an
atmosphere of 5% CO2 and 95% humidity. Cells were grown to 80–90% of confluence in sterile cell
culture flasks. Sub-confluent monolayer cells were used in all experiments. The cell line was provided
by cell bank of the University of Granada, Spain.
3.8. Cell Viability Assay
The effect of each treatment with compounds 1, 2, 3, or 4 in RAW 264.7 murine macrophage
cells was measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
proliferation assay (Sigma, MO, USA), which is based on the ability of live cells to cleave the tetrazolium
ring, thus producing formazan, which absorbs at 570 nm [64].
Cell viability was determined by measuring the absorbance of MTT dye staining of living cells.
For this assay, 6 × 103 RAW 264.7 cells were grown on a 96-well plate and incubated with compounds
1, 2, 3, and 4 respectively, at different concentrations (0–100 µg/mL). Lately, after 72 h of incubation,
100 µL of MTT solution (0.5 mg/mL) in 50% of PBS 50% of medium was added to each well. After
1.5 h of incubation formazan was re-suspended in 100 µL of DMSO. Relative cell viability, with respect
to untreated control cells, was measured by absorbance at 570 nm on an ELISA plate reader (Tecan
Sunrise MR20–301, TECAN, Austria).
3.9. Determination of Nitrite Concentration
Nitrite concentration was used as indicator of NO production. NO determination was based on
Griess reaction [65].
Cells were plated at 6 × 104 cells/well in 24-well cell culture plates and supplemented with
10 µg/mL of LPS. After 24 h of plated, cells were incubated for 24 h with compounds 1, 2, 3, and 4 at
3/4 × IC50, 1/2 × IC50, 1/4 × IC50 concentrations. The supernatants were collected to determine their
nitrite concentration and/or stored at –80 ◦C for further use.
Griess reaction was performed taking 150µL of supernatant test samples or sodium nitrite standard
(0–120 µM) and mixed with 25 µL of Griess reagent A (0.1% N-N-(1-naphthyl)-ethylenediamine
dihydrochloride) and 25 µL of Griess reagent B (1% sulfanilamide in 5% of phosphoric acid), in a
96-well plate. After 15 min of incubation at room temperature, the absorbance was measure at 540 nm
in an ELISA plate reader (Tecan Sunrise MR20-301, TECAN, Austria). The absorbance was referred to
nitrite standard curve to determine the concentration of nitrite in the supernatant of each experimental
sample. The percentage of NO production was determined, assigning 100% at the increase between
negative control (untreated cells) and positive control (cells only treated with 10 µg/mL of LPS).
3.10. Cell Cycle Analysis
Flow cytometry is a quick novel method to determine efficiently and reproducibly the relative
DNA content, ploidy as well as to measure alterations in cell cycle profiles. DNA content is directly
proportional to the PI fluorescence, which allows to determine the percentage of cell in each cell cycle
phase. In this way, we could visualize cellular subpopulations, with different DNA contents. Changes
in DNA levels are characteristic of cell cycle arrest and cell differentiation.
The number of cells in each stage of the cell cycle was estimated by fluorescence-associated cell
sorting (FACS) at 488 nm in an Epics XL flow cytometer (Coulter Corporation, Hialeah, FL, USA).
For this assay 12 × 104 RAW 264.7 murine macrophage/monocyte cells stimulated with LPS were plated
in 24-well plates with 1.5 mL of medium and incubated with the compounds under study for 24 h,
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at 3/4 × IC50 and 1/2 × IC50 concentrations, as we described above. Several controls were analyzed
in a parallel way; a positive control was performed with cells treated only with LPS stimulation,
and a negative control where RAW 264.7 cells were exposed to the compounds under study without
lipopolysacharide stimulation. After treatment, cells were washed twice with PBS and harvested by
tripsinization, then were re-suspended in TBS 1X (10Mm Tris, 150Mm NaCl) and subsequently added
Vindelov Buffer (100 mM Tris, 100 MmNaCl, 10 mg/mL Rnasa, 1 mg/mL PI, pH 8). The samples were
allowed to stand for 15 min on ice. Immediately before FACS analysis, cells were stained with 20 µL of
1 mg/mL PI solution. Data were analyzed to determine the percentage of cells in each cell cycle phase
(G0/G1, S, and G2/M).
3.11. Statistics
Statistical and non-lineal regression analyses were performed with the SigmaPlot 12.5 software.
All quantitative data were summarized as the means ± standard deviation (SD). All data shown here
were representative of at least two independent experiments performed in triplicate.
4. Conclusions
Two novel cobalt coordination compounds using bumetanide and indomethacin therapeutic
agents have been synthesized. These compounds present mononuclear structures and show slow
relaxation of the magnetization. Regarding the anti-inflammatory assays, were performed under
sub-citotoxic concentrations of the compounds in this study (1, 2, 3, and 4) to ensure that the possible
anti-inflammatory effect was exclusively due to their anti-inflammatory properties and not to their
cytotoxic effects. For this reason 3/4 IC50, 1/2 IC50, and 1/4 IC50 concentrations were used in the further
assays. All products assayed present anti-inflammatory effects at the concentrations used, being
able to revert the 100% cell cycle arrest in the G0/G1 phase induced by LPS in RAW 264.7 murine
monocyte/macrophage cells, however, no significant differences were found in the cell cycle effects for
the different products assayed. Moreover, our results showed that indomethacin-Co complex, was
six times more effective than its ligand (indomehtacine) in the inhibition of NO production, whereas
non-significant differences in the NO inhibition were found between bumetanide-Co complex and
bumetanide. The EC50 NO, for the compound 3 was calculated being 28.76 ± 4.23 µg/mL, after 24 h of
treatment. Concerning antidiabetic properties, results suggest that compounds 1 and 3 are endowed
with antidiabetic properties as demonstrated by the lower glucose content found in C. elegans when
compared with non-treated nematodes. For future in vivo studies, it remains to be analyzed whether
the new complexes modify in any way the side effects shown by indomethacin and bumetanide at
the gastrointestinal level. In conclusion, our results reveal that the synthesis of metal complexes with
bioactive ligands is a new and promising strategy to find new compounds with high and enhanced
biochemical properties.
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Abbreviations
NO Nitric oxide
MAPK Mitogen-activated protein kinases
JAK Janus-activated kinases
PI3K/AKT Phosphatidylinositol-3-kinase
STAT Signal transducer activator of transcription
NF-kB Nuclear factor kappa B
AP-1 Activation proteins 1
HIF-1 Hypoxia inducible factor 1-α
iNOS Nitric oxide synthase inducible
COX-2 Cyclooxyenase-2
LPS Bacterial lipopolysaccharide
TNFα Tumor necrosis factor α
INF- γ Interferon-γ
NSAID Nonsteroidal anti-inflammatory drug
COX Cyclooxygenase enzyme
CCDC Cambridge Crystallographic Data Centre
QTM Quantum tunneling of the magnetization
ZFS Zero-field splitting
SIM Single ion magnet
DPPH 2,2-Diphenylpicrylhydrazyl
IC50 Total concentration to obtain a 50% growth inhibition
EC50 Dosages that give around 50% of the maximum possible drug effect
IP Propidium iodide
ROS Reactive oxygen species
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